Scott Applebaum

Chief Legal Officer, Corporate Secretary at VectivBio

Speaker

Scott Applebaum is the Chief Legal Officer and VectivBio, a clinical stage biotech focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need.  He brings over two decades of legal, regulatory and operational experience in the biopharmaceutical industry to VectivBio.

Prior to joining VectivBio, Mr. Applebaum was the Chief Legal & Compliance Officer and Senior Vice President of Regulatory Affairs at Trevena, where he played a key role in gaining FDA approval for their lead product, Olinvyk®. Previously, he served as President of Context Therapeutics and was General Counsel at Vitae Pharmaceuticals, where he was instrumental in their sale to Allergan. Formerly, he was Chief Legal Officer for Medgenics, a rare genetic disease company. Mr. Applebaum spent 10 years at Shire, where his roles included heading up its global legal group, managing their neuroscience portfolio outside of the United States as SVP of the Neuroscience Business Unit and leading the implementation and execution of the regulatory strategy for all of Shire’s specialty pharmaceutical products worldwide as SVP of Global Regulatory Affairs, Quality Assurance and Compliance. Previously, he was Senior Counsel for medicines and medical imaging at Bristol Myers Squibb.   Mr. Applebaum also serves on the board of Cingulate Therapeutics (Nasdaq: CING).

Prior to his career in the biopharmaceutical industry, Mr. Applebaum was a lawyer at Dechert LLP. He received his J.D. from Stanford Law School and a B.S. in Economics, Finance and Accounting from the Wharton School of the University of Pennsylvania.